SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

January 26th, 2017 – People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers diagnosed worldwide. The trial is called DART (Dual Anti–CTLA-4 and Anti­–PD-1 Blockade in Rare Tumors) and is managed by SWOG, the cancer clinical … (leggi tutto)